John V. Oyler
Senior Vice Founder and CEO, BeiGene
John Oyler is a serial entrepreneur with a track record of success. John has raised over $270 million in capital, each round providing positive returns. John is most known for building highly functional, passionate, world-class organizations.
Currently, John is Founder & CEO of BeiGene. BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region. It was founded by Dr. Xiaodong Wang, Head of The National Institute of Biologic Sciences in Beijing and Member of National Academy of Sciences, USA; Dr. Peter Ho, Former VP of Oncology Development at Johnson & Johnson; and Dr. Pearl Huang, Former VP Integrator and Head of Biomarker Discovery and Early Development Strategy for Oncology at Merck.
John has also started several companies such as BioDuro (sold to PPD), a 670+ person research company in Beijing that was a leader in its vision and ability to successfully undertake in fully integrated programs; Galenea , a private drug discovery company developing drugs for CNS and respiratory disease; Genta (GNTA), a publicly traded company which later grew to a market capitalization of over $US1.6 billion; and Telephia, an information services company for the telecommunications industry that was purchased by Nielsen for just under $500 million.
He spent four years at McKinsey where he spent 1992-3 working in China. He holds a BS from MIT and an MBA from Stanford.